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Human immunodeficiency virus (HIV) induces a chronic generalized activation of the 25 
immune system, which plays an important role in the pathogenesis of AIDS. This ability 26 
of the virus might either be an evolved (adaptive) trait or a coincidental side-effect of 27 
jumping to a new host species. We argue that selection favours the ability of HIV to 28 
induce immune activation at the local sites of infection (e.g. lymph follicles), but not at 29 
the systemic level. Immune activation increases the supply of susceptible target cells; 30 
however, mutations that increase systemic immune activation benefit all virus variants 31 
equally, and are therefore selectively neutral. We thus conclude that the generalized 32 
immune activation that is likely responsible for pathogenesis is probably not directly 33 




Accumulating evidence indicates that the pathogenesis of HIV infection is linked to the 36 
ability of the virus to induce a chronic generalized hyperactivation of the immune system [1-37 
4]. Activation status is a strong predictor of disease progression [5-8], with consistent effect in 38 
HIV-1 and HIV-2 in spite of different virus levels [9]; and the ongoing depletion of CD4+ T 39 
cells has been associated with accelerated turnover due to chronic activation [2,4,10]. 40 
Understanding the proximate and ultimate (evolutionary) causes of HIV induced immune 41 
activation may be the key to understanding pathogenesis. In this Opinion article, we 42 
concentrate on the evolutionary background of this pathogenic mechanism. 43 
HIV has its origin and closest relatives in the group of simian immunodeficiency viruses (SIV) 44 
[11,12]. Remarkably, immune hyperactivation is absent in African primates naturally infected 45 
with SIV, and these infections are indeed largely nonpathogenic [13-15]. From the 46 
perspective of the virus, this raises the question of whether immune activation is an evolved 47 
(adaptive) trait of HIV or an “unwanted” side-effect of jumping to a new host species, which 48 
may be lost during subsequent evolution. Drawing on mathematical and simulation models, 49 
we argue that it may actually be both: raising immune activation in a local microenvironment 50 
provides selective advantage for the virus, but the induction of systemic immune activation 51 
(associated with pathogenesis) is likely to reflect an evolutionary accident. We begin with a 52 
discussion of how immune activation may benefit the virus, and then show when (and 53 
whether) this benefit translates to a selective advantage that can drive evolution. 54 
 55 
How could immune activation be beneficial for HIV? 56 
 4 
Activating immune cells is generally thought to benefit HIV by increasing its supply of 57 
susceptible target cells [16,17]. HIV replicates most efficiently in activated CD4+ T 58 
lymphocytes, while quiescent cells that form the majority of this cell population are less 59 
susceptible to productive infection [18-20], and produce less virus when infected compared 60 
with activated cells [21,22]. HIV can activate and infect CD4+ T cells that recognize one of its 61 
epitopes [23,24]; however, the majority of activated CD4+ T cells are not HIV-specific 62 
[23,25]. Bystander activation of uninfected CD4+ T cells has been demonstrated to increase 63 
susceptibility to infection and subsequent virus production ex vivo [17]. In vivo, the 64 
percentage of activated cells (as measured by activation markers, e.g. KI67, HLA-DR or 65 
CD25) increases during disease progression [7], which maintains the supply of target cells in 66 
the face of a declining overall CD4 count. Finally, increased immune activation by 67 
vaccination or unrelated infections generally increases the HIV virus load in infected patients 68 
[26-30]. Activating CD4+ T cells thus seems to be clearly beneficial for the virus. However, 69 
this benefit translates to a selective advantage only if it favours the activator virus against its 70 
competitors in the diverse virus population of an infected host. This criterion is central to our 71 
argument, and below we show why it is not necessarily fulfilled. 72 
 73 
Systemic vs. local immune activation 74 
The main mechanism of HIV induced (bystander) immune activation has not yet been 75 
clarified, although there is no shortage of candidates: molecular mimicry of gp120 providing 76 
false MHC type II signals [31], Nef-mediated lymphocyte activation [32], the effect of 77 
abundant defective virus particles [16], altered cytokine production [33], dysregulation of 78 
tumor necrosis factor receptor signalling [34], unchecked translocation of bacterial products 79 
into the systemic circulation due to the disruption of the gut mucosa [35], or the induction of 80 
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Toll-like receptors by HIV RNA [36] have all been implicated, and may operate 81 
simultaneously. Importantly, most of these effects can potentially spread beyond the 82 
immediate neighbourhood of a virus-producing cell (by virus particles or shed viral proteins 83 
entering the circulation, or by indirect stimuli mediated by cytokines or translocated bacterial 84 
products), and are likely to contribute to the generalized immune activation that is associated 85 
with pathogenesis. We therefore distinguish between systemic immune activation that, in the 86 
simplest approximation, affects the baseline activation of all target cells, and local immune 87 
activation, which is confined to the neighbourhood where the inducer virus was produced. 88 
The two types of immune activation have drastically different evolutionary implications, and 89 
whether they can be decoupled could be crucial for the future evolution of HIV virulence (the 90 
severity of the disease). Note that real biological mechanisms of immune activation are likely 91 
to fall somewhere in between the theoretical extremes (completely global or completely local 92 
effect) that we analyze here: long-range effects tend to behave as our systemic model, while 93 
short-range effects are better described by the local activation model. 94 
Mutations affecting systemic immune activation are selectively neutral 95 
Systemic immune activation increases the supply of susceptible target cells for the whole 96 
virus population; however, it confers no selective advantage for the virus variants that induce 97 
it. The reason for this is that the increased “global” availability of target cells benefits all virus 98 
variants equally, irrespective of whether they contributed to immune activation or not. An 99 
arising mutant with improved efficiency of systemic immune activation will therefore not be 100 
able to increase in frequency, and the ability to induce systemic immune activation is not 101 
expected to be under selection. This argument can be tested formally using mathematical 102 
models (Box 1). A robust prediction of the models is that the induction of systemic immune 103 
activation is indeed evolutionarily neutral for HIV, even though it is expected to increase the 104 
total virus level. A population level benefit is thus not necessarily translated into a selective 105 
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advantage in competition within the virus population. The induction of systemic immune 106 
activation can essentially be regarded as an “altruistic” trait for the virus, which benefits other 107 
“individuals” (or viral lineages) in addition to the carrier of the trait. We will discuss this 108 
interpretation in more detail later. 109 
Local immune activation confers selective advantage 110 
The lack of selection on systemic immune activation results from all viruses activating all 111 
target cells equally. However, some of the activation effect is likely to be limited to the 112 
neighbourhood of the inducer virus. HIV infects cells and is produced primarily in the 113 
lymphoid tissues [37,38], which have a highly organized spatial structure. Virus samples 114 
isolated from different sections of an infected spleen display markedly different genetic 115 
composition even on a microscopic scale [39-42], which suggests that aggregates of target 116 
cells can be colonized by a single or a few “founder” viruses and may serve as relatively 117 
isolated local sites for several rounds of virus replication [4,43,44]. Phylogenetic analyses of 118 
multiple virus isolates from individual patients have also hinted at a “metapopulation” 119 
structure involving the dynamic establishment and extinction of distinct local HIV 120 
subpopulations within a single patient [45-47]. Finally, localized activation by exogenous 121 
antigens has been demonstrated to fuel a local expansion of SIV clones [48]. These data 122 
suggest that HIV induced immune activation could partly be restricted to the neighbourhood 123 
of the inducer virus, which might influence the evolution of this trait. The effect of such 124 
spatial structure can be investigated in a simulation model involving a dynamic 125 
metapopulation of local “bursts of infection” (Box 2). The simulations illustrate that, in 126 
contrast to systemic activation, the ability to induce local immune activation provides 127 
selective advantage to HIV (Box 3). This result arises because the benefit of locally increased 128 
target cell supply is not shared equally by all virus types, but can be exploited by the virus 129 
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that induced it in a given microenvironment. We thus conclude that the evolution of HIV 130 
favours the ability to induce local, but not systemic immune activation. 131 
Immune activation as an altruistic viral trait 132 
The different evolutionary outcome of local and systemic immune activation is consistent 133 
with earlier work on the general evolutionary theory of altruistic traits. In particular, our 134 
model of local immune activation resembles “structured deme models”, which were first 135 
proposed by Wilson to explain how random group formation can facilitate the spread of 136 
beneficial traits that would be excluded by “selfish mutants” in a homogeneous population 137 
[49,50]. In our model, the ability to induce systemic immune activation provides a population 138 
level benefit (increased overall virus load) for the virus, but activator mutants cannot spread in 139 
the population. In fact, assuming any metabolic (or, in general, fitness) cost associated with 140 
the ability of immune activation would result in competitive exclusion of activator viruses by 141 
“selfish” non-activating mutants in the systemic model. The local structure of HIV infections 142 
creates a “trait-group” structure sensu Wilson [49,50], and this structure indeed promotes the 143 
selection for local immune activation in computer simulations. Structured deme models have 144 
been used before to explore the evolution of multi-component viruses and defective 145 
interfering virus particles [51], but this is their first application to the evolution of HIV 146 
pathogenesis. 147 
The evolution of “unselfish” viral traits (i.e. traits that confer advantage only at the population 148 
level) has been addressed before in the context of viral strategies towards immune function 149 
impairment [52]. We note that our argument can be extrapolated to speculate that “altruistic” 150 
viral traits that contribute to the impairment of HIV specific immune responses could also be 151 
selected within the host if their effect were confined to the local sites of infection. 152 
Implications for HIV evolution 153 
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Our results have implications for the evolutionary history and future evolution of HIV 154 
pathogenesis. While the mechanism of systemic immune activation in HIV infection is still 155 
unclear, there is an indirect clue to its nature. Most observed cases of SIV transmission to 156 
non-adapted hosts (humans and Asian macaques) have resulted in AIDS-like disease with 157 
immune pathology [15], which suggests that the ability to induce systemic immune activation 158 
in non-adapted hosts is a conserved “pre-adaptation” among SIV viruses. Evolutionary 159 
conservation suggests maintenance by selection, and the ability to increase local target cell 160 
supply may be a plausible candidate for this pre-adaptation. While we have demonstrated that 161 
systemic immune activation per se is probably neutral for the virus, it may nevertheless arise 162 
as a side-effect of the ability to induce target cell activation at the local sites of infection, 163 
which is probably under selection. The example of nonpathogenic natural SIV infections 164 
raises the hope that the two phenomena can be decoupled. The high virus load characteristic 165 
of these infections suggests efficient local immune activation, while systemic immune 166 
activation is absent from the infected hosts. How this decoupling occurs is currently unknown; 167 
however, the observation that the same SIV strain can cause chronic activation and 168 
pathogenesis in non-adapted, but not in adapted natural hosts [15] points out the role of host 169 
factors. If systemic immune activation is indeed neutral for the virus, then selection acting on 170 
the virus would neither drive nor oppose evolution towards the loss of systemic activation and 171 
pathogenesis. Such evolution would, however, clearly benefit the host and could, in the 172 
absence of opposing viral selection, be driven by the evolution of host factors [53]. 173 
We note that our models have concentrated on HIV evolution occurring within an infected 174 
host; selection acting on transmission between hosts may add further complexity [52]. In 175 
particular, if systemic immune activation is required to maintain the high virus loads that 176 
ensure efficient transmission, then evolution may stabilize the efficiency of systemic 177 
activation (and ensuing virulence) at an optimal level [54]. However, HIV evolution seems to 178 
 9 
be largely dominated by the selection forces acting within hosts [55], which reduces the 179 
strength of this constraint, while a decoupling of efficient transmission from systemic immune 180 
activation (as in nonpathogenic SIV infections) would remove this selection constraint 181 
entirely. In the latter case, the virus might even gain by losing systemic immune activation, if 182 
the life span of infected hosts could increase without compromising their infectiousness. 183 
However, even in this scenario, the selection pressure driving HIV towards decreasing 184 
systemic immune activation might be weak, for two reasons. First, selection acting on the 185 
transmission of HIV between hosts seems to be weak compared to selection acting within the 186 
host [55], and we have demonstrated that systemic immune activation is likely to be neutral in 187 
terms of the latter. Second, a large fraction of new infections seem to result from transmission 188 
during acute infection [56], which further reduces the strength of selection acting on virus 189 
traits that influence host survival. Therefore, we predict that attenuation of HIV might occur, 190 
but the timescale of this process will be set by slow stochastic (neutral) evolution, rather than 191 
by rapid selection against systemic immune activation. Evolution of hosts to resist systemic 192 
activation might have accelerated (or entirely driven) the process of attenuation in natural SIV 193 
infections. However, this evolutionary pathway is highly undesirable for the human disease of 194 
HIV infection, since it could only proceed by the differential survival (and death) of infected 195 
patients depending on their susceptibility to systemic activation. 196 
Finally, we note that within-host evolution towards increasing immune activation could, in 197 
principle, contribute to HIV disease progression [57,58], if two criteria are fulfilled. First, 198 
local and systemic immune activation should remain coupled on the time scale of within-host 199 
evolution so that evolution of the former would drive that of the latter. Second, the efficiency 200 
of activation should be host-specific, so that its evolution could occur repeatedly and 201 
independently in the infection of each individual. This could be plausible if the activation 202 
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signal depended on receptor-mediated lymphocyte activation, which is extremely variable due 203 
to high MHC polymorphism and the random generation of the receptor repertoire. 204 
Implications for anti-activation treatment 205 
Future therapeutic strategies might target HIV induced systemic activation to reduce 206 
pathogenesis. Such drugs will affect interactions between the virus and the immune system, or 207 
the immune system alone, rather than directly inhibit a step in the viral lifecycle as current 208 
drugs do. This raises the question whether the virus could evolve “resistance” against such 209 
therapies. According to our results, drugs affecting systemic (but not local) immune activation 210 
selectively would not put a selection pressure on the virus, and therefore the efficacy of the 211 
drugs would not be jeopardized by the evolution of resistance. In contrast, drugs affecting 212 
local immune activation might elicit viral evolution to restore the efficiency of local activation. 213 
The spread of such “resistant” super-activator viruses could actually increase virulence at the 214 
population level. The long-term success of this potential therapeutic approach might thus 215 
depend on our ability to identify and selectively inhibit the viral mechanisms of systemic 216 
immune activation. 217 
Conclusion 218 
We have argued that local, but not systemic immune activation is likely to provide selective 219 
advantage to HIV within an infected host. Systemic immune activation and the resulting 220 
immune pathogenesis are thus likely to reflect a coincidental side-effect of cross-species 221 
transmission, rather than adaptation to a new (human) host. Systemic immune activation 222 
might be lost during further evolution, but this might occur slowly or might require adaptation 223 
of the human host. Further work should concentrate on elucidating the mechanisms of HIV 224 
induced immune activation. Of particular interest is the range of the effects, which determines 225 
their evolution; and whether short and long-range effects can be decoupled, which may shape 226 
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the future of HIV virulence and might also affect the success of future drugs that will target 227 
immune activation. 228 
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Box 1. Mathematical model of systemic immune activation 371 
Adapting the established framework of virus dynamics [59] to the scenario of systemic 372 
immune activation yields the following set of equations: 373 
 (1a-c) 374 
The model comprises of quiescent CD4+ target cells, Q, activated target cells, T, and 375 
productively infected cells, I. Quiescent CD4+ target cells arise at a constant rate σ, die at rate 376 
δQQ and become activated at an intrinsic (HIV-independent) rate αQ. HIV-dependent 377 
bystander activation of quiescent cells occurs at rate kIQ, where the parameter k denotes the 378 
efficiency of activation. Activated target cells, T, die at rate δTT, revert to resting state at rate 379 
rT and become infected at a rate proportional to the abundance of productively infected cells, 380 
I, and the infection efficiency parameter β. Infected cells die at rate δII. For simplicity, we 381 
only allowed for the infection of activated cells in the basic model, and did not represent the 382 
level of free virus, which typically follows the level of virus-producing cells. This system is 383 
structurally similar to some earlier models [58,60]. The scheme of the model is shown in 384 
Figure Ia. 385 
To investigate whether the ability to induce systemic immune activation is under selection, we 386 
modelled competition between two virus variants (I1 and I2) that differed only in their 387 
efficiency in activating quiescent CD4+ T cells (such that k1 > k2): 388 
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 (2a-d) 389 
A simplified scheme of the competition model is shown in Figure Ib. It can be shown 390 
analytically that the ratio of the two virus variants remains constant over time irrespective of 391 
the choice of parameters. This implies that when a new variant with altered activation 392 
efficiency is introduced (by mutation or superinfection) into a chronic infection with a 393 
resident virus, it will persist at its initial frequency, but will neither exclude nor be excluded 394 
by the resident virus type. Mutations that affect systemic immune activation are thus 395 
selectively neutral and the evolution of this trait is not expected to be driven by natural 396 
selection. Importantly, this result is independent of the equations that describe the dynamics 397 
of quiescent and activated target cells. The result is thus robust with respect to the processes 398 
that affect these cell populations, and depends only on the assumption that both virus variants 399 
have access to the same pool of activated cells (which is equivalent to all target cells being 400 
equally affected by the overall level of systemic activation). 401 
402 
 17 
Box 2. Simulation model of local immune activation 402 
Our simulation model consisted of a large number (n=1000) of spatially separated local sites 403 
of infection (e.g. lymph follicles or aggregates of target cells) and a systemic pool (e.g. blood 404 
or lymph) that received and mixed the output of all sites. Infection of each site (equivalent to 405 
a “burst of infection”) was initiated with a defined number of uninfected quiescent and 406 
activated target cells, and one or several “founder viruses” that were sampled randomly from 407 
the systemic pool. To maintain consistency with the systemic model, the infection of each site 408 
was simulated as an independent copy of the basic model (equation 2a-d). Considering that 409 
the infection of local sites is probably short-lived compared to the dynamics of quiescent cells, 410 
the influx rate of these cells was set to zero. All other parameter values were set to 411 
biologically plausible values, and initial values were set to reflect the overall frequency (2%) 412 
of activated lymphocytes. For simplicity, each site was terminated after 100 simulation steps 413 
(corresponding to 10 days), by which time most target cells were typically exhausted. In vivo, 414 
local bursts of infection may also be terminated by HIV specific cytotoxic lymphocytes that 415 
infiltrate the site and kill infected cells. The initial age of local infections was randomized at 416 
the beginning of a simulation, and new sites were initiated at each simulation step to maintain 417 
the steady-state number of active sites. At each step, the overall ratio of the two virus variants 418 
was computed by summing the two types of infected cells over all infected sites. New sites 419 
were colonized according to a Poisson process, with the expected (mean) number of founder 420 
viruses varied between simulations. The type of the founder viruses was determined randomly 421 
(following a binomial distribution) according to the overall ratio of the two types. This 422 
corresponds to assuming a systemic pool that mixes the output of all sites and serves as a 423 
source of randomly sampled founder viruses (or infected cells) for the colonization of new 424 
sites. The model thus combined continuous, deterministic virus dynamics within individual 425 
sites and discrete, stochastic dynamics at the level of the metapopulation of all sites. 426 
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Considering that little quantitative data are available on the dynamics of the local sites of 427 
infection, our model aimed at a qualitative description of the dynamics. The scheme of the 428 
model is shown in Figure II. 429 
430 
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Box 3. Mutations affecting local immune activation are selected 430 
In typical simulations of the local activation model (Box 2), the virus variant with increased 431 
efficiency of local immune activation (“activator type”) expands over time, and the variant 432 
with weaker immune activation eventually goes extinct (Figure IIIa). Increased efficiency of 433 
local immune activation thus provides selective advantage, even though within each site the 434 
initial ratio of the two variants is preserved throughout the lifetime of the site. This result 435 
arises because of two factors. First, random sampling of a small number of founder viruses 436 
generates variation in the initial ratio of the two variants at newly initiated sites. E.g. sampling 437 
two founder viruses per site from a systemic pool with 10% activator type mostly yields both 438 
founders from the weakly activating type; however, some of the sites will have one, and about 439 
1% will have both founders from the activator type. Second, the initial ratio of the activator 440 
type influences virus production at a given site: more activator virus results in faster and more 441 
profound activation and infection of the local stock of target cells. Thus, founder samples with 442 
higher activator ratios experience stronger amplification, and therefore the frequency of the 443 
activator type increases over time in the whole population. As long as these two criteria are 444 
fulfilled, the result is very robust in terms of both the structure and the parameters of the 445 
model. E.g., allowing for entry of new uninfected cells to a site during the lifespan of the site 446 
can delay the extinction of the weakly activating type (by reducing the relative advantage of 447 
the activator type gained from its faster initial expansion), but cannot prevent this outcome in 448 
most simulations. Allowing for entry of further infected cells from the systemic compartment 449 
in small numbers comparable to the initial founder sample has numerically negligible effect 450 
on the outcomes. 451 
To demonstrate the importance of the “founder effect”, we varied its strength by varying the 452 
(mean) number of founders that colonize a new site. As expected, the time to the fixation of 453 
the activator type (defined as the complete disappearance of the weakly activating type in a 454 
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simulation) increases with the number of founders (Figure IIIb), i.e. the selective advantage of 455 
local immune activation decreases as the founder effect becomes weaker. In theory, the 456 
founder effect is abolished completely if the number of founders approaches infinity, or if the 457 
ratio of the activator type can assume any real number between 0 and 1 and is allowed to 458 
follow the exact ratio in the systemic mixing pool. In this limit, the simulation model would 459 
approximate the homogeneous systemic model that yielded no selective advantage for the 460 
ability of immune activation. However, an analysis of HIV quasispecies indicated that local 461 
sites of infection may be colonized by a single virus variant [47], which implies the strongest 462 
possible founder effect. 463 
464 
 21 
Box 4. Outstanding questions 464 
What is the main mechanism of HIV induced immune activation? At present, there are 465 
many candidates [16,31-33,35,36], but no certain answer. Of particular interest for further 466 
evolution is the range of the activation effect. While most candidate mechanisms could have 467 
stronger local than systemic effects, this is not necessarily true for indirect mechanisms, like 468 
bacterial translocation through the gut mucosa [35]. 469 
Why are SIVs pre-adapted to induce systemic immune activation in non-adapted hosts? 470 
Our hypothesis suggests that SIVs may have evolved to induce local immune activation, and 471 
it may be this mechanism that also inadvertently causes systemic activation in non-adapted 472 
hosts. Understanding the original role of the mechanism in naturally infected primates may 473 
provide important clues to why it goes awry in humans. Repeating the experiment of 474 
Biancotto et al. [17] with lymphoid tissue isolated from natural SIV hosts and infected ex vivo 475 
with species specific SIV might reveal whether the efficiency of local activation is indeed 476 
important in natural SIV infections. 477 
Is systemic activation just the sum of local activation effects, or something more? 478 
Whether systemic activation is a side-effect of local activation, and if so, whether it can be 479 
decoupled from the latter seems crucial for the future evolution of HIV induced immune 480 
pathogenesis. Obligate coupling between the two types of activation could maintain current 481 
levels of pathogenesis due to stabilizing selection acting on the efficiency of local immune 482 
activation. 483 
What is the typical founder size? The simulations suggest that the fragmentation of the virus 484 
population within a host, in particular, the number of viruses that infect a local site, has a 485 
marked effect on the strength of selection favouring (local) immune activation. More data are 486 
needed to estimate this quantity. 487 
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Figure I. (a) Scheme of the basic model of systemic immune activation. (b) Simplified 489 
scheme of the extended model with two competing virus variants. The activation effect of 490 
both variants is summed up in the overall activation rate of target cells, and the two variants 491 




Figure II. Scheme of the simulation model of local immune activation [TO BE INCLUDED 494 




Figure III. (a) The activator type goes to fixation in the simulation of local immune 497 
activation. The boxplot depicts the ratio of the activator type over time from 100 simulations. 498 
Red boxes indicate the interquartile range of the ratio at each time point; median is indicated 499 
by a horizontal line within the box, and whiskers extend to the farthest values that are not 500 
more than 1.5 times the box width away from the box. The expected number of founders was 501 
set to 5, and simulations were started with 10% activator type. (b) Time to fixation of the 502 
activator type as a function of the expected number of founders in the simulation model. 100 503 
simulations were performed for each value of the expected number of founders 504 
(parameterizing the Poisson process of new site initialization); competitive exclusion was 505 
registered when the variant with lesser activation efficiency was lost completely from the 506 
system. The boxplot shows the median (horizontal lines), the interquartile range (green boxes) 507 
and the farthest values that are not more than 1.5 times the box width away from the box 508 
(whiskers) for the lengths of time that elapsed till competitive exclusion for each parameter 509 
value. Weaker founder effect (more founders) increased the time to fixation indicating 510 
decreasing selective advantage for the activator type. All simulations were started with 10% 511 
activator type and shared the following parameters: α=0.012 d-1, β=0.1 d-1/cell, δI=1 d-1, 512 
δT=0.2 d-1, δQ=0.001 d-1, k1=0.009 d-1/cell, k2=0.003 d-1/cell, r=0.4 d-1; initial values within 513 
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each site: T(0)=20, Q(0)=1000; number of sites: 1000, lifespan of sites: 10 d (see box 1 for 514 
definitions). [TO BE INCLUDED IN BOX 3] 515 
